This observation is in accordance with results of other authors, for example, Rubin et al. [22] for the first time determined that ovarian cancer associated with BRCA1 mutations had a more favorable clinical course, and it was confirmed by other studies in which this advantage in survival of mutation carriers was reported to be an independent protective factor [23]. Here, BRCA1 is linked to ovarian carcinoma.